Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphomas and multiple myeloma (MM). While data pertaining to the efficacy and toxicity associated with CAR-T have been widel...

Full description

Saved in:
Bibliographic Details
Main Authors: Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma, Don Benson, Francesca Cottini, Evandro Bezerra, Jonathan Brammer, Naresh Bumma, Hannah Choe, Nathan Denlinger, Srinivas Devarakonda, Abdullah Khan, Sam Penza, Ashley Rosko, Sumithira Vasu, Sarah Wall, Lapo Alinari, Robert Baiocchi, David A. Bond, Beth Christian, Walter Hanel, Kami Maddocks, John Reneau, Yazeed Sawalha, Alma Habib, Audrey Sigmund, Timothy J. Voorhees, Marcos de Lima, Narendranath Epperla
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Journal of Hematology & Oncology
Subjects:
Second primary malignancies
SPM
CAR-T
LBCL
MM
Online Access:https://doi.org/10.1186/s13045-025-01676-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13045-025-01676-4

Similar Items